Andrew is Head of Commercialisation at the University of Bristol where he manages the team responsible for licensing and new company creation. He also manages his existing portfolio of projects in Health Sciences where he facilitates the translation and commercialisation of a broad range of technologies and healthcare interventions.
Andrew is a Registered Technology Transfer Professional and has 20 years experience in Technology Transfer roles, first at the University of West of England and then at the University of Bristol. He is an experienced non-executive director who has been on the board of a number of therapeutic, medical device and public health focused spin-out companies.
Andrew has led and supported a large number of spin-out transactions, including Purespring Therapeutics (a Syncona-backed renal gene therapy company) and IRISi Ltd (an award-winning social enterprise established to promote and improve the healthcare response to domestic violence and abuse).